| Original language | English |
|---|---|
| Journal | Clinical and Experimental Dermatology |
| Volume | 47 |
| Issue number | 8 |
| Pages (from-to) | 1585-1586 |
| Number of pages | 2 |
| ISSN | 0307-6938 |
| DOIs |
|
| Publication status | Published - 2022 |
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa? / Ring, Hans Christian; Frew, John W.; Thyssen, Jacob P.; Egeberg, Alexander; Thomsen, Simon F.
In: Clinical and Experimental Dermatology, Vol. 47, No. 8, 2022, p. 1585-1586.Research output: Contribution to journal › Comment/debate › Research › peer-review
}
TY - JOUR
T1 - Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?
AU - Ring, Hans Christian
AU - Frew, John W.
AU - Thyssen, Jacob P.
AU - Egeberg, Alexander
AU - Thomsen, Simon F.
N1 - Funding Information: No funding for the study. JPT is supported by a grant from the Lundbeck Foundation. Funding Information: HCR has received research funding from the Kgl Hofbundtmager Aage Bang Foundation and honoraria as speaker from Leo Pharma. JWF has conducted advisory work for Janssen, Boehringer‐Ingelheim, Pfizer, Kyowa Kirin, LEO Pharma, Regeneron, Chemocentryx, AbbVie and UCB, participated in trials for Pfizer, UCB, Boehringer‐Ingelheim, Eli Lilly, CSL and Janssen, and received research support from Ortho Dermatologics and Sun Pharma. JPT is an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron and Sanofi‐Genzyme, a speaker for AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron and Sanofi‐Genzyme, and received research grants from Pfizer, Regeneron and Sanofi‐Genzyme. AE has received research funding from Pfizer, Eli Lilly, Novartis, Bristol‐Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd. Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co. Ltd. Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol‐Myers Squibb, and Janssen Pharmaceuticals. SFT has been a speaker and/or served on advisory boards for AbbVie, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB, and has received research support from AbbVie, Janssen, LEO Pharma, Novartis, Sanofi and UCB. The authors declare that they have no conflict of interest.
PY - 2022
Y1 - 2022
U2 - 10.1111/ced.15232
DO - 10.1111/ced.15232
M3 - Comment/debate
C2 - 35437813
AN - SCOPUS:85131180908
VL - 47
SP - 1585
EP - 1586
JO - Transactions of the St. John's Hospital Dermatological Society
JF - Transactions of the St. John's Hospital Dermatological Society
SN - 0307-6938
IS - 8
ER -